Revium Rx (RVRC) Completes Acquisition of LipoVation Ltd.
Revium Rx (RVRC) has completed the acquisition of LipoVation , an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. The acquisition positions Revium at the forefront of advanced drug delivery technologies and marks a strategic shift toward nanoparticle-based therapeutics.
The company's pipeline includes three key programs: a novel systemic antibiotic formulation, an adjuvant for cancer immunotherapies, and an innovative immunization approach. These therapeutics are built on proprietary technologies including clinically validated nanoparticles, advanced drug-loading systems, and specialized lipid-based carriers.
Following the acquisition, David Akunis has been appointed CEO, while former CEO Inna Martin has transitioned to COO and President. LipoVation's core technology was developed by Prof. Yehezkel Barenholz, inventor of Doxil, the first FDA-approved liposomal chemotherapy drug.
Revium Rx (RVRC) ha completato l'acquisizione di LipoVation, un'azienda israeliana in fase di sviluppo specializzata in medicinali a base di nanoparticelle e microparticelle lipidiche. L'acquisizione colloca Revium in prima linea nelle tecnologie avanzate di rilascio dei farmaci e segna un cambiamento strategico verso le terapie basate su nanoparticelle.
Il portafoglio dell'azienda include tre programmi chiave: una nuova formulazione antibiotica sistemica, un adiuvante per le immunoterapie oncologiche e un approccio innovativo all'immunizzazione. Questi terapeutici si basano su tecnologie proprietarie tra cui nanoparticelle clinicamente validate, sistemi avanzati di caricamento dei farmaci e trasportatori lipidici specializzati.
In seguito all'acquisizione, David Akunis è stato nominato CEO, mentre l'ex CEO Inna Martin è passata a COO e Presidente. La tecnologia fondamentale di LipoVation è stata sviluppata dal Prof. Yehezkel Barenholz, inventore di Doxil, il primo farmaco chemioterapico liposomiale approvato dalla FDA.
Revium Rx (RVRC) ha completado la adquisición de LipoVation, una empresa israelí en etapa de desarrollo especializada en medicamentos a base de nanopartículas y micropartículas lipídicas. La adquisición posiciona a Revium a la vanguardia de las tecnologías avanzadas de administración de medicamentos y marca un cambio estratégico hacia terapias basadas en nanopartículas.
El pipeline de la empresa incluye tres programas clave: una nueva formulación de antibióticos sistémicos, un adyuvante para inmunoterapias contra el cáncer y un enfoque innovador para la inmunización. Estos terapéuticos están construidos sobre tecnologías patentadas que incluyen nanopartículas validadas clínicamente, sistemas avanzados de carga de medicamentos y transportadores lipídicos especializados.
Tras la adquisición, David Akunis ha sido nombrado CEO, mientras que la ex CEO Inna Martin ha pasado a ser COO y Presidenta. La tecnología central de LipoVation fue desarrollada por el Prof. Yehezkel Barenholz, inventor de Doxil, el primer medicamento de quimioterapia liposomal aprobado por la FDA.
Revium Rx (RVRC)가 이스라엘 개발 단계 기업인 LipoVation을 인수했습니다. LipoVation은 지질 기반의 나노/미세 입자 의약품을 전문으로 합니다. 이번 인수는 Revium을 고급 약물 전달 기술의 최전선에 위치시켰으며, 나노입자 기반 치료제로의 전략적 전환을 의미합니다.
회사의 파이프라인에는 세 가지 주요 프로그램이 포함되어 있습니다: 새로운 전신 항생제 제형, 암 면역 요법을 위한 보조제, 그리고 혁신적인 면역화 접근 방식입니다. 이 치료제들은 임상적으로 검증된 나노입자, 고급 약물 로딩 시스템 및 특수 지질 기반 운반체를 포함한 독점 기술을 바탕으로 구축됩니다.
인수 이후 David Akunis가 CEO로 임명되었고, 이전 CEO인 Inna Martin은 COO 및 회장으로 이동했습니다. LipoVation의 핵심 기술은 FDA 승인 첫 번째 리포좀 화학요법 약물인 Doxil의 발명자인 Yehezkel Barenholz 교수에 의해 개발되었습니다.
Revium Rx (RVRC) a finalisé l'acquisition de LipoVation, une entreprise israélienne en phase de développement spécialisée dans les médicaments à base de nanoparticules et de microparticules lipidiques. Cette acquisition place Revium à la pointe des technologies avancées de délivrance de médicaments et marque un virage stratégique vers des thérapeutiques basées sur des nanoparticules.
Le pipeline de l'entreprise comprend trois programmes clés : une nouvelle formulation d'antibiotiques systémiques, un adjuvant pour les immunothérapies contre le cancer et une approche d'immunisation innovante. Ces thérapeutiques sont basées sur des technologies propriétaires, y compris des nanoparticules cliniquement validées, des systèmes avancés de chargement de médicaments et des transporteurs lipidiques spécialisés.
Suite à l'acquisition, David Akunis a été nommé PDG, tandis que l'ancienne PDG Inna Martin est devenue COO et Présidente. La technologie principale de LipoVation a été développée par le Prof. Yehezkel Barenholz, inventeur de Doxil, le premier médicament de chimiothérapie liposomale approuvé par la FDA.
Revium Rx (RVRC) hat die Übernahme von LipoVation abgeschlossen, einem israelischen Unternehmen in der Entwicklungsphase, das auf lipidbasierte Nano-/Mikropartikelmedikamente spezialisiert ist. Diese Übernahme positioniert Revium an der Spitze fortschrittlicher Arzneimittelabgabetechnologien und markiert einen strategischen Wechsel hin zu therapeutischen Ansätzen, die auf Nanopartikeln basieren.
Das Pipeline des Unternehmens umfasst drei Schlüsselprogramme: eine neuartige systemische Antibiotika-Formulierung, ein Adjuvans für Krebsimmuntherapien und einen innovativen Immunisierungsansatz. Diese Therapeutika basieren auf proprietären Technologien, einschließlich klinisch validierter Nanopartikel, fortschrittlicher Arzneimittelbeladungssysteme und spezialisierten lipidbasierten Trägersystemen.
Nach der Übernahme wurde David Akunis zum CEO ernannt, während die ehemalige CEO Inna Martin zur COO und Präsidentin gewechselt ist. Die Kerntechnologie von LipoVation wurde von Prof. Yehezkel Barenholz entwickelt, dem Erfinder von Doxil, dem ersten von der FDA zugelassenen liposomalen Chemotherapeutikum.
- Acquisition of LipoVation brings proven nanoparticle drug delivery technology
- Technology backed by inventor of FDA-approved Doxil
- Development of three promising therapeutic programs
- Strategic restructuring with experienced leadership appointment
- All pipeline products still in development stage
- No immediate revenue generation from acquired technology
- Significant R&D investments likely needed for clinical development
Revium Rx Shifts Focus with Acquisition of LipoVation Ltd., Advancing Nanoparticle-Based Drug Development
Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- February 4, 2025 – Revium Rx (formerly Revium Recovery Inc., OTC: RVRC) has completed the strategic acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. This acquisition marks a significant shift in Revium Rx’s focus toward nanoparticle-based therapeutics, positioning the company at the forefront of advanced drug delivery technologies for hard-to-treat diseases.
LipoVation’s core technology was conceptualized by Prof. Yehezkel Barenholz, a world-renowned scientist and the inventor of Doxil, the first FDA-approved liposomal chemotherapy drug, widely used in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation.
Pipeline & Technology Focus
Revium Rx is developing a portfolio of advanced therapeutics, currently in the development stage, aimed at expanding the potential of existing treatments. Key programs include:
- A novel systemic formulation of a highly potent antibiotic, previously limited to topical use, designed to combat antibiotic-resistant bacterial infections.
- A cutting-edge adjuvant to enhance immune checkpoint inhibitors, improving the efficacy of cancer immunotherapies.
- An innovative approach to immunization, leveraging novel peptides and lipid-based technology for emerging infectious diseases.
These next-generation encapsulated therapeutics are built on three core proprietary technologies:
- Clinically validated nanoparticles for targeted drug delivery.
- Advanced drug-loading and release systems to optimize bioavailability.
- Specialized lipid-based carriers for enhanced stability and controlled release.
Leadership & Strategic Direction
Following the acquisition, David Akunis has been appointed as Chief Executive Officer (CEO) of Revium Rx, bringing extensive managerial experience and financial expertise to drive the company’s new direction. With a strong background in fundraising and leadership, he is dedicated to advancing Revium Rx’s mission of developing innovative nanoparticle-based therapeutics and expanding the company’s impact in the pharmaceutical industry.
Inna Martin, who has served as CEO since December 2020, has transitioned to Chief Operating Officer (COO) and President, focusing on product development and clinical trial preparation. This strategic shift ensures that Revium Rx progresses rapidly toward clinical-stage development while expanding strategic partnerships and accelerating growth.
“As the demand for safer and more effective treatments continues to grow, our mission is to expand and enhance the therapeutic potential of existing treatments by utilizing proven drug delivery technologies to improve efficacy, safety, and clinical outcomes,” said David Akunis, CEO of Revium Rx. “Revium Rx's encapsulated therapeutics platform represents a transformative step forward in the fight against resistant infections, cancer, and emerging infectious diseases.”
With this new strategic direction, Revium Rx continues to expand its research and development efforts, forging key partnerships and advancing its pipeline of highly potent therapeutics.
For more information, visit www.reviumrx.com or contact:
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. Neither Revium Rx nor LipoVation are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company Contact:
Inna Martin
1-800-5191687
FAQ
What is the strategic significance of RVRC's acquisition of LipoVation ?
What are the main therapeutic programs in RVRC's pipeline after the LipoVation acquisition?
Who are the key leadership changes at RVRC following the LipoVation acquisition?
What proprietary technologies did RVRC acquire through the LipoVation deal?
How does the LipoVation acquisition affect RVRC's market position?
